RareResearch.AI
← Back to atlas

W700C

Category 3/4 — Most DruggablePathogenicLumenal · predictedσ-1 candidateEditorial
TryptophanCysteine at position 700 · C-terminal lumenal domain (653-869) · WFS1 (Wolframin)

Tryptophan → Cysteine at position 700 in wolframin's C-terminal lumenal domain. ClinVar Pathogenic (the stronger classification tier). AlphaMissense 0.999, DynaMut2 ΔΔG -0.10 kcal/mol — essentially no destabilization. A pathogenic variant where the fold cost is negligible: the damage is mechanistic, not structural.

Interactive 3D Structure

Wild-type reference
Wild-type W700 — hydrogen bond to F825
Fullscreen ↗
DynaMut2 mutant · W700C
Mutant C700 — hydrogen bond to L664 lost (10 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

10 lost1 gained6 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondL664Lost
Hydrogen bondW666Gained
Hydrogen bondE824E824Preserved
Hydrogen bondF825F825Preserved
Polar contactL664Lost
Polar contactE824E824Preserved
Polar contactF825F825Preserved
Aromatic / πW666Lost
Aromatic / πY669Lost
HydrophobicW666Lost
HydrophobicY669Lost
HydrophobicV698Lost
HydrophobicM781M781Preserved
HydrophobicI802Lost
HydrophobicF825F825Preserved
HydrophobicL829Lost
HydrophobicF840Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.10kcal/mol
Destabilising — mild
AlphaMissense
0.999
LPath
AlphaFold pLDDT
90
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationPathogenic
Review statuscriteria provided, single submitter
Associated conditions(no specific conditions catalogued for W700C — ClinVar Pathogenic classification established by review evidence)
InheritanceInheritance not specified in this ClinVar entry. The W700 position is documented in multiple pathogenic contexts; mechanism inference suggests AD given dominant-negative potential from aberrant disulfide formation.
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.2100G>C
ClinVar accessionVCV003011532
Last evaluated2024/10/07 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Structural Context

Position 700 sits in wolframin's C-terminal lumenal domain (residues 653–869). In the AlphaFold model, W700 is packed against immediate sequence neighbors THR699 (2.5 Å) and THR701 (2.4 Å), and into a distant aromatic-hydrophobic pocket containing PHE825 (3.9 Å) and MET781 (4.8 Å). The wild-type indole ring contributes π-stacking to PHE825 and hydrophobic contact to MET781 — substantial packing density into a defined local environment.

Replacing tryptophan with cysteine here removes the bulky aromatic indole entirely and replaces it with a small thiol. The volume difference is large — roughly 100 ų — but the resulting cavity is partially filled by the surrounding atoms relaxing slightly, and the new free thiol does not introduce charge or strong polarity. This explains the surprisingly small |ΔΔG| of 0.10 kcal/mol: DynaMut2 reports the fold is essentially unperturbed.

The contrast with W700S (same position, serine substitution) is the structural lesson. W700S has |ΔΔG| of 2.49 kcal/mol — Category 2, moderately destabilizing — because the polar hydroxyl introduces unfavorable contacts in the hydrophobic pocket. W700C, with a thiol instead of a hydroxyl, sits closer to the chemistry the pocket can tolerate. Yet both are pathogenic, with W700C carrying the stronger 'Pathogenic' ClinVar classification.

The inference: W700's pathogenic mechanism is not primarily structural destabilization. The lost interaction — likely the π-stacking with PHE825 — is functional rather than fold-critical. The indole at W700 probably mediates a specific protein-protein interaction surface or a fold-locking contact whose loss is functionally severe even when the fold itself remains intact. Additionally, the newly introduced free thiol in the ER lumen's oxidative environment may form aberrant disulfide bonds with nearby cysteines (such as C673 or C690 in the same domain), introducing a misfolding pressure that DynaMut2's predicted ΔΔG cannot fully capture.

Amino-acid chemistry
Tryptophan (W) → Cysteine (C) — the bulkiest aromatic side chain replaced by a small thiol-bearing residue. Loss of aromatic packing and indole H-bonding; introduction of a reactive free thiol in an oxidizing lumenal environment.
Position in the protein
C-terminal lumenal domain · position 700 sits in the ER lumen, in a high-confidence region (pLDDT 90). The oxidative ER lumen environment is the relevant context for a newly-introduced cysteine residue.

Druggability Assessment

Category 3/4 — Most Druggable. |ΔΔG| = 0.10 kcal/mol — the fold is essentially intact. AlphaMissense 0.999 confirms severe functional consequence despite the negligible structural cost. This is the most extreme example in the Windsor Set of the pathogenicity-without-destabilization profile.

The mechanism is the loss of a specific functional interaction — likely the π-stacking surface between W700 and PHE825 — plus the introduction of a free thiol that may participate in aberrant disulfide formation in the oxidative ER lumen. Neither mechanism collapses the fold; both produce severe functional consequence.

The therapeutic strategy is site-directed small-molecule design that either re-creates the lost W700-PHE825 contact (via an aromatic small molecule that occupies the pocket) or blocks the aberrant cysteine disulfide chemistry (via a thiol-protective small molecule). The cleanest druggability profile in the Atlas: maximum pathogenicity, minimum fold disruption, defined target geometry.

Why this matters

W700C exemplifies the Atlas's deepest finding: pathogenicity and fold destabilization are NOT the same axis. A variant can carry AlphaMissense 0.999 (near-maximum pathogenic signal) and ΔΔG essentially zero (no fold cost). When that happens, the mechanism is specific — a lost contact, a broken interaction surface, a chemistry change in a critical site — and the therapeutic vector is site-directed small molecules, not gene therapy and not chaperones. W700C is the single cleanest example in the Atlas of why structure-based drug design is the right strategy for the majority of WFS1 variants.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the W700C PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download W700C PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Topological domain653869 · Lumenal
Natural variant700700 · in WFS1